Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accounts Payables (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Accounts Payables for 9 consecutive years, with $6.0 million as the latest value for Q1 2026.

  • For Q1 2026, Accounts Payables fell 46.25% year-over-year to $6.0 million; the TTM value through Mar 2026 reached $6.0 million, down 46.25%, while the annual FY2025 figure was $9.7 million, 38.78% down from the prior year.
  • Accounts Payables hit $6.0 million in Q1 2026 for Bicycle Therapeutics, down from $9.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $18.3 million in Q2 2025 and bottomed at $2.8 million in Q1 2023.
  • Average Accounts Payables over 5 years is $8.6 million, with a median of $7.1 million recorded in 2024.
  • Year-over-year, Accounts Payables skyrocketed 301.51% in 2022 and then tumbled 46.25% in 2026.
  • Bicycle Therapeutics' Accounts Payables stood at $6.5 million in 2022, then skyrocketed by 101.64% to $13.0 million in 2023, then increased by 21.02% to $15.8 million in 2024, then plummeted by 38.78% to $9.7 million in 2025, then tumbled by 38.26% to $6.0 million in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $6.0 million, $9.7 million, and $12.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.